REHOVOT, Israel and JERSEY CITY, New Jersey, April 28 Rosetta Genomics (Nasdaq: ROSG), a leadingdeveloper of microRNA-based diagnostics and therapeutics, announced todaythat it has signed a non-exclusive licensing agreement with RockefellerUniversity for research application of proprietary microRNA genes. Theagreement encompasses viral and human microRNAs that will be added to RosettaGenomics' existing intellectual property (IP) estate, which includes twoissued patents, two allowed patent applications, and 60 pending patentapplications.
"As leaders in the microRNA field, we view our strong intellectualproperty position as a key component of our business strategy, allowing usthe freedom to advance the company and its pipeline." said Amir Avniel,President and CEO of Rosetta. "Our strategy continues to focus onsupplementing our in-house IP portfolio with licensing agreements with keyacademic centers such as Rockefeller University."
Rosetta Genomics has previously licensed Rockefeller University'sproprietary microRNAs for therapeutic and diagnostic uses, and this recentagreement allows the company access to a full range of potential microRNAapplications based on these microRNAs.
In addition to its non-exclusive license of Rockefeller University'smicroRNAs, Rosetta Genomics estimates it has exclusive access to the majorityof known microRNA genes through proprietary microRNAs discovered at RosettaGenomics and microRNAs co-discovered by The Johns Hopkins University Schoolof Medicine and exclusively licensed to the Company. In addition, the Companyhas non-exclusively licensed for research and diagnostic applicationsmicroRNAs discovered by the Max Planck Society. From this strong IP position,Rosetta Genomics is developing a wide range of microRNA-based diagnostictests for cancer and other indications.
MicroRNAs (miRNAs) are recently discovered, naturally occurring, smallRNAs that act as master regulators and have the potential to form the basisfor a new class of diagnostics and therapeutics. Since many diseases arecaused by the abnormal activity of proteins, the ability to selectivelyregulate protein activity through microRNAs could provide the means to treata wide range of human diseases. In addition, microRNAs have been shown tohave different expression in various pathological conditions. As a result,these differences may provide for a novel diagnostic strategy for manydiseases.
About Rockefeller University
The Rockefeller University is a world-renowned center for research andgraduate education in the biomedical sciences, chemistry, and physics.Founded by John D. Rockefeller in 1901, the university has been the site ofmany important scientific breakthroughs. Rockefeller scientists establishedthat DNA is the chemical basis of heredity, discovered blood groups, showedthat viruses can cause cancer, founded the modern field of cell biology, andworked out the structure of antibodies. Twenty-three Nobel Prize winners havebeen associated with the university.
For more information please visit: http://www.rockefeller.edu
About Rosetta Genomics
Rosetta Genomics (Nasdaq: ROSG) is a leader in the field of microRNA.Founded in 2000, the company's integrative research platform combiningbioinformatics and state-of-the-art laboratory processes has led to thediscovery of hundreds of biologically validated novel human microRNAs .Building on its strong IP position and proprietary platform technologies,Rosetta Genomics is working on the application of these technologies in thedevelopment of a full range of microRNA-based diagnostic and therapeutictools, focusing primarily on cancer and various women's health indications.The company expects that the first microRNA diagnostic tests applying itstechnology will be launched by licensed clinical laboratories in the UnitedStates in 2008. http://www.